BMO Capital Markets’s $36 target on TRVI

TRVI Trevi Therapeutics Inc

$13.3 → $36 (+170%) by Oct 2027

Outperform · reiterates · said Oct 7, 2026 · 12-month default horizon

Open: judged on the close on Oct 7, 2027

The article this target came from

BMO reiterates Trevi Therapeutics stock rating after rival study fails

Investing.com · Oct 7, 2026

BMO Capital reiterated an Outperform rating and $36.00 price target on Trevi Therapeutics ([NASDAQ:TRVI](https://www.investing.com/equities/trevi-therapeutics-inc)) shares following a competitor's clinical trial failure.

BMO Capital Markets’s track record → Trevi Therapeutics Inc →

A fact about what BMO Capital Markets published, as reported by Investing.com, not a recommendation from Dalsna Finance; BMO Capital Markets is not affiliated with this site.

Full methodology: how targets are collected, scored, ranked and corrected, what each field means, and how to cite the data.